R&D Post-hype, pre-value: The real AI-pharma shift starts now The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
R&D When is the superbug message going to bite? As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
R&D From data to impact: How real-world evidence will transform ... Real-world evidence (RWE) has moved from the periphery to the centre of how healthcare decisions are made.
R&D Maximising value by uniting the digital backbone: On a new N... Novo Nordisk and Veeva have entered into a new partnership for clinical development.
R&D Changing Faces – Pharma and biotech hires – May 2025 The pharmaceutical and biotechnology sectors witnessed significant leadership changes this month, with numerous high-profile appointments spanning from established commercial-stage companie
R&D GRIN Therapeutics: Seeking to address unmet needs in rare ne... Dr Bruce Leuchter, CEO of GRIN Therapeutics and Neurvati Neurosciences, discusses the companies GRIN-NDD work with pharmaphorum.
News ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
